Ann Bunker
Adult Health · Lower Gwynedd, PANPI 1861878753
Payments from drug & device makers
Across 60 payments — averaging $39.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$654
- Amgen$273
- Lilly USA, LLC$242
- Ardelyx, Inc.$149
- Novartis$119
- Optinose US, Inc.$115
- plus $823 from 15 others
What the payments were for
- Food & beverage$2,375100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 12 | $654 |
| Amgen | 4 | $273 |
| Lilly USA, LLC | 6 | $242 |
| Ardelyx, Inc. | 5 | $149 |
| Novartis | 5 | $119 |
| Optinose US, Inc. | 1 | $115 |
| Gilead | 1 | $94 |
| Insmed, Inc. | 1 | $87 |
| Aurinia Pharma U.S., Inc. | 3 | $86 |
| Boston Scientific | 1 | $77 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Boehringer Ingelheim | 3 | $60 |
| Fresenius USA Marketing, Inc. | 3 | $59 |
| Bayer | 3 | $55 |
| Coloplast | 1 | $55 |
| OPKO Pharmaceuticals, LLC | 2 | $40 |
| Travere Therapeutics, Inc. | 2 | $40 |
| Calliditas Therapeutics US Inc. | 1 | $31 |
| Vifor Pharma, Inc. | 1 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,375 in reported general payments places this provider in the 80th percentile of 899 adult health providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 121 | $126,026 |
| JardianceEmpagliflozin | 60 | $39,063 |
| ProcritEpoetin Alfa | 13 | $19,051 |
| Cinacalcet Hcl | 41 | $13,447 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $12,282 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $11,689 |
| Nifedipine ErNifedipine | 234 | $8,367 |
| Sevelamer Carbonate | 60 | $4,042 |
| Losartan Potassium | 197 | $3,016 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,707 |
| Clonidine | 15 | $1,765 |
| Carvedilol | 148 | $1,485 |
| Calcium Acetate | 20 | $1,362 |
| Valsartan | 29 | $1,350 |
| Hydralazine Hcl | 44 | $1,150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $654 | $138,308138 claims |
| Boehringer IngelheimJardiance | $60 | $39,06360 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Lower Gwynedd
- Beth SandyPhiladelphia$924K
- Diane NewmanPhiladelphia$413K
- Jennifer MondilloSchwenksville$396K
- Elizabeth FaustDouglassville$356K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Lauren MassimoPhiladelphia$139K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.